Breakthrough Prize honors life-changing cystic fibrosis treatment and cancer pioneer with $3 million awards

The chemists behind the development of Trikafta, a triple-drug combination that has significantly improved the lives of people with cystic fibrosis, have been awarded the prestigious Breakthrough Prize. Sabine Hadida, Paul Negulescu, and Fredrick Van Goor at Vertex Pharmaceuticals developed the treatment by combining different drugs that help a faulty protein to function. Trikafta has been hailed as one of the most remarkable achievements in biomedical research in the last 30 years. The Breakthrough Prize, which awards achievements in life sciences, physics, and mathematics, also recognized breakthroughs in Parkinson's disease research, CAR-T-cell immunotherapy for leukemia, and the study of conformal field theories in physics.